Every 8-K that Kewaunee Scientific Corp (KEQU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KEQU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KEQU filings page.
Kewaunee Scientific Corporation (KEQU) reported softer results for the first quarter of fiscal 2027 ended July 31, 2026, with net sales of $66.3 million, down 6.7% from $71.1 million a year earlier. Net earnings attributable to the company were $1.7 million versus $3.1 million, and diluted EPS declined to $0.58 from $1.04. Consolidated EBITDA fell to $4.5 million from $6.3 million.
The Lab Products Group segment delivered sales of $50.9 million (down 6.4%), with segment net earnings of $3.9 million and EBITDA of $6.6 million, as cost controls and efficiencies helped offset lower life sciences volumes. International segment sales were $15.5 million (down 7.8%), but segment net earnings rose 23.5% to $0.8 million and segment EBITDA increased 13.9% to $1.2 million on a higher-margin project mix.
Order backlog increased sequentially to $169.0 million at July 31, 2026 from $165.9 million at April 30, 2026, though it remained below $205.0 million a year earlier. Long-term debt, excluding the sale-leaseback financing obligation, declined to $13.8 million from $15.1 million at April 30, 2026, and the debt-to-equity ratio improved slightly. Corporate results were pressured by non-recurring compensation expense from settling specific long-term incentive awards in cash rather than shares.
KEWAUNEE SCIENTIFIC CORP (KEQU) reported results of its August 26, 2026 Annual Meeting of Shareholders. Shareholders re-elected Class I directors Thomas D. Hull III, David S. Rhind, and John D. Russell to three-year terms, each receiving over 1.46 million votes in favor.
Shareholders also ratified the appointment of Forvis Mazars, LLP as independent registered public accounting firm for fiscal 2027, with 2,516,379 votes for and very few opposing or abstaining votes. On an advisory "say-on-pay" basis, compensation of named executive officers for the year ended April 30, 2026 was approved, receiving 1,586,496 votes for, compared with 36,616 against.
Kewaunee Scientific Corporation (KEQU) used its annual meeting investor presentation to highlight continued growth and balance-sheet strengthening for fiscal year 2026, ended April 30, 2026. Revenue reached $282.0 million, extending a multi‑year growth trajectory and representing nearly a 14% CAGR since fiscal 2021.
EBITDA increased to $22.4 million, growing at nearly a 157% CAGR over five years, while consolidated order backlog was $165.9 million, down from $214.6 million as large international projects were completed. Long‑term debt was reduced by about $20 million, improving the debt‑to‑equity ratio to 0.61‑to‑1.0 from 0.99‑to‑1.0.
The renamed Lab Products Group (formerly Domestic) delivered $214.9 million in sales, up 19.8%, driven by a full year of NuAire results, with EBITDA of $25.1 million. International sales rose to $67.1 million and EBITDA to $5.9 million, supported by delivery of previously delayed projects in India. Kewaunee also emphasized investments in SOX 404(b) readiness, governance, systems, and international expansion to support further organic and acquisition‑driven growth.
KEWAUNEE SCIENTIFIC CORP (KEQU) announced that it plans to release its first quarter fiscal year 2027 financial results on Wednesday, September 9, 2026, after the close of trading. The results will be made available on the company’s website.
Kewaunee Scientific also reiterates its role as a global provider of laboratory, healthcare, and technical furniture, with manufacturing operations in North Carolina, Minnesota, and India, and sales or warehouse partnerships across the United States, Europe, the Middle East, and Asia. The announcement includes standard forward-looking statement cautions referencing risk factors in its Form 10-K for the year ended April 30, 2026.
Kewaunee Scientific Corporation reported fiscal year 2026 sales of $281,999,000, up 17.3% from the prior year, reflecting growth in both its Lab Products Group and International segments. Full-year net earnings were $9,618,000, with diluted EPS of $3.22, compared to $3.83 a year earlier.
EBITDA for the year was $22,425,000, slightly above the prior year, while adjusted EBITDA reached $23,210,000 after excluding Nu Aire integration costs. The company reduced long-term debt to $40,851,000 and improved its debt-to-equity ratio to 0.61-to-1, ending the year with order backlog of $165.9 million. Fourth-quarter sales were $71,400,000, with net earnings of $3,388,000 and diluted EPS of $1.13.
Kewaunee Scientific Corporation filed a current report stating it will release financial results for its fourth quarter and fiscal year ended April 30, 2026 on June 23, 2026 after the close of trading. The results will be posted on the company’s website.
The filing also highlights Kewaunee’s global business in laboratory, healthcare, and technical furniture, and notes its newly acquired subsidiary Nu Aire, a manufacturer of biological safety cabinets and other laboratory equipment. The press release includes standard forward-looking statement language outlining various business risks and uncertainties.
Kewaunee Scientific Corporation reported mixed results for its third quarter ended January 31, 2026. Sales were $69.4 million, up 3.3% from $67.2 million a year earlier, and consolidated EBITDA was $3.8 million, slightly above $3.7 million.
Despite higher sales, net earnings attributable to Kewaunee fell to $0.7 million, down from $1.4 million, with diluted EPS declining to $0.23 from $0.45. Domestic sales decreased 2.0%, while international sales grew 21.4%, lifting international segment EBITDA to $2.0 million from $0.8 million.
The order backlog was $183.2 million versus $221.6 million a year earlier, reflecting softer construction-related activity. The company reduced long-term debt from $60.7 million on April 30, 2025, to $42.3 million, improving its debt-to-equity ratio to 0.68-to-1 from 0.99-to-1 as it continues integrating the Nu Aire acquisition and investing in its corporate platform.
Kewaunee Scientific Corporation announced that it plans to release its third quarter fiscal year 2026 financial results on March 11, 2026, after the close of trading. The results will be posted on the company’s website.
The company describes itself as a global provider of laboratory, healthcare, and technical furniture and related equipment, and notes that its portfolio now includes products from its newly acquired subsidiary, Nu Aire.
Kewaunee Scientific Corporation filed a Form 8-K to let investors know when its next financial results will be issued. The company plans to release its second quarter fiscal 2026 earnings on December 10, 2025. This notice is an administrative update and does not include any financial results or guidance. The related earnings press release is identified as Exhibit 99.1 to the report.
Kewaunee Scientific announced the appointment of Mr. Campbell to its Board and approved amended bylaws. Mr. Campbell brings extensive finance and restructuring experience from roles at Carl Marks Advisors and prior executive positions at Griffin LLC, PepsiCo and Frito-Lay, and is a certified public accountant with decades in public accounting and corporate finance. The Board determined he meets Nasdaq and SEC independence and financial literacy requirements and has named him to the Audit Committee.
The company said Mr. Campbell will be paid under the standard non-employee director program and will receive a pro-rated equity grant for fiscal 2026. The Board also amended Section 5.02 of the Bylaws to set the Board size at a minimum of five and maximum of nine directors, with the exact number fixed by Board resolution.
Kewaunee Scientific Corporation filed a current report to let investors know it has released financial results for the first quarter of its fiscal year 2026. The company states that these results were announced in a press release dated September 10, 2025, which is provided as Exhibit 99.1.
The report explains that this press release is being furnished, rather than filed, which limits how it is treated under securities laws. Kewaunee’s common stock continues to trade on the Nasdaq Global Market under the symbol KEQU.
Kewaunee Scientific Corporation reported the results of its Annual Meeting of Shareholders held on August 27, 2025. Shareholders re-elected Class III directors Margaret B. Pyle and Donald F. Shaw, with Pyle receiving 1,633,067 votes for and 189,229 withheld, and Shaw receiving 1,730,171 votes for and 92,125 withheld, along with 537,449 broker non-votes for each nominee.
Shareholders ratified the appointment of Forvis Mazars, LLP as independent auditors for fiscal 2026, with 2,356,636 votes for, 2,119 against, and 990 abstentions. On an advisory basis, shareholders approved the compensation of the named executive officers with 1,448,991 votes for, 103,177 against, 270,128 abstentions, and 537,449 non-votes.
In an advisory vote on the frequency of future say-on-pay votes, shareholders favored holding the vote every one year, with 1,512,884 votes for one year, 1,194 for two years, 306,985 for three years, 1,233 abstentions, and 537,449 non-votes. The company will include an annual non-binding advisory vote on executive compensation in its proxy materials consistent with this outcome and the Board’s recommendation.
Kewaunee Scientific Corporation filed a current report to let investors know when it will share its next results. The company announced that it plans to release its first quarter fiscal 2026 earnings on September 10, 2025. This update is provided through a press release that is attached to the report as an exhibit and incorporated by reference.
Kewaunee Scientific Corporation furnished an investor presentation and related script in connection with its virtual Annual Meeting of Shareholders held at 11:00 a.m. Eastern time on August 27, 2025. These materials, attached as Exhibits 99.1 and 99.2, are also available in the Investor Information section of the company’s website and a replay of the audio webcast of the meeting will remain accessible for about one year. The company uses non-GAAP financial measures in the presentation and provides reconciliations to comparable GAAP measures in the same location. The materials also include forward-looking statements, and the company points investors to its Form 10-K for the year ended April 30, 2025 and other SEC filings for a discussion of risk factors that could cause actual results to differ.
Kewaunee Scientific (Nasdaq: KEQU) filed a Form 8-K on June 25 2025 to furnish Item 2.02 – Results of Operations and Financial Condition. The company released its fourth-quarter and fiscal-year results for the period ended April 30 2025 via a press release, attached as Exhibit 99.1.
The information is expressly treated as "furnished," not "filed," thereby avoiding Section 18 liability and limiting incorporation into future SEC documents unless specifically cited. No other reportable events were disclosed.